YUNNAN BAIYAO(SZ:000538)2024-06-18 09:57Group 1: Sales Performance and Growth - Other brand traditional Chinese medicine products achieved significant growth in 2023, with sales of Pudilan Anti-inflammatory Tablets and Huoxiang Zhengqi Water exceeding 100 million yuan, increasing by nearly 16% and 124% year-on-year respectively [1] - The sales revenue of Gonyang Ning Capsules, used for gynecological inflammation, rose by 47% year-on-year [1] - In the oral care sector, Yunnan Baiyao toothpaste maintained a market share of 24.60% in 2023, ranking first in the domestic market [2] Group 2: Marketing Strategies - During the "Double 11" shopping festival, Yunnan Baiyao's official flagship store for toothpaste achieved over 100 million yuan in sales for the first time, becoming the first flagship store to do so with a single toothpaste product [2] - The company implemented a dual-channel strategy, enhancing brand exposure through online and offline promotions, including over 14,700 offline promotional events covering 1,465 cities [2] Group 3: Supply Chain Development - Yunnan Baiyao focuses on long-term strategies for major traditional Chinese medicine varieties, establishing a standardized full industry chain for key medicinal materials like Chuanxiong and Sanqi [3][4] - The company has successfully transformed the wild breeding of Chuanxiong into a marketable and industrialized medicinal material through two decades of efforts [4] Group 4: Investor Returns - Since its listing, Yunnan Baiyao has distributed over 24.4 billion yuan in cash dividends, with a 2023 dividend proposal of 20.77 yuan per 10 shares, totaling 3.706 billion yuan, which accounts for 90.53% of the net profit attributable to shareholders [5] - The company repurchased 12,599,946 shares, approximately 0.7015% of the total share capital, with a repurchase cost exceeding 700 million yuan, and completed the cancellation of these shares in April 2024 [5]